12 October, 2020
Skadden advised Everest Medicines Limited on its listing and initial public offering on the Main Board of The Hong Kong Stock Exchange Limited. The company issued 63,547,000 shares at HK$ 55 each for a total offer value of HK$ 3.495 billion (US$ 451 million). Everest Medicines Limited is a biopharmaceutical company founded by C-Bridge Capital to focus on licensing, clinical development and commercialization of potentially novel or differentiated therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. Trading commenced on 9 October 2020.
The Skadden team was led by Hong Kong partners Julie Gao, Christopher Betts, and Paloma Wang, and Shanghai partner Haiping Li, with Counsel Kenneth Chase (Hong Kong), associates Steven Lee(Hong Kong), Lu Ma (Hong Kong), Paul Lau (Hong Kong), Xiaoxi Gong (Shanghai), and Ming Kong (Hong Kong), and trainee solicitors Hillary Chan (Hong Kong) and Shu Fei (Marie) Lim (Hong Kong).
